NCT02087540

Efficacy and Safety of Telmisartan/Rosuvastatin Co-administration in Hypertensive Patients With Hyperlipidemia

A Randomized, Double-blind, Multi-center, Factorial Phase III Clinical Trial to Evaluate the Efficacy and Safety of Telmisartan/Rosuvastatin Co-administration in Hypertensive Patients With Hyperlipidemia

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 310 (estimated)
• Sponsor: IlDong Pharmaceutical Co Ltd · Industry
• Sex: All
• Age: 19 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

To identify efficacy and safety of Telmisartan/Rosuvastatin co-administration in hyperlipidemia control in hypertensive patients with hyperlipidemia compared to each monotherapy.

Conditions

• Hypertension
• Hyperlipidemia

Interventions

Type	Name	Description
DRUG	Telmisartan 80mg
DRUG	Rosuvastatin 20mg
DRUG	Rosuvastatin 10mg
DRUG	Placebo(for Telmisartan 80mg)
DRUG	Placebo(for Rosuvastatin 20mg)
DRUG	Placebo(for Rosuvastatin 10mg)

Timeline

• Start date: 2013-05-01
• Primary completion: 2014-12-01
• First posted: 2014-03-14
• Last updated: 2014-03-14

Locations

1 site across 1 country: South Korea